Products

Cervical cancer is the third most common cancer among women worldwide despite teh availability of HPV vaccines. Cervical intraepithelial neoplasia (CIN) grade 2 and 3 (-pre-malignant) lesions are considered high-gade squamous intraepithelial leasions (HSILs). It is caused by infection with high-risk Human Papillomavirus (HPV). Over 60% of HSILs are caused by HPV16. Annually, 1.1 to 1.4 million HPV16 HSIL new cases accur globally.

Our first product candidate Vvax001, an RNA replicon based immunotherapy against (pre)malignant cervical lesions, is currently in clinical development. Our strategy involves saRNA encoded fusion E6 and E7 protein resulting in high expression for induction or stimulation of cytotoxic T lymphocyte (CTL) activity against HPV-transformed cells.

Succesfully comleting Phase II trial we are focused on funding the Phase III trial. In view of the current landscape, VVax001 has the potential of becoming a First-in-Class HPV16-specific cervical immunotherapy and could be a serious alternative to the standard of care as a non-invasive treatment (no surgical risks, preserves fertility), clearing HPV16 and a strong safety and tolerability profile.